The adaptive approach for Zytiga has been studied. nature.com/articles/s41467-...
BAT has been shown to resensitize cancer cells to Zytiga and Xtandi (the last study that I saw showed a moderate resensitization to Zytiga but very good resensitization to Xtandi).
Zytiga adaptive approach is part of SPT/Deca/ADT-SARMs. The linked research study focuses on Zytiga. Zytiga is used in the ADT-SARMs phase and discontinued in the SPT/Deca phases.
I'm still working on this program and testing it in real-time. Last month my PSA was 0.13, then 0.17 the following week. I started the ADT-SARMs phase in late September and now my PSA is undetectable.